Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost
Through Equity Subscription Agreement
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
You may also be interested in...
Rather than terminating a deal for the French biotech's VLA2001 vaccine, the European Commission has put in a tiny order of 1.25 million doses which could bring the curtain down on Valneva's COVID-19 programs.
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.
The MHRA has become the first regulatory agency worldwide to grant a marketing authorization for the inactivated whole virus COVID-19 vaccine, VLA2001.